/Investor DB

Pappas Capital — 2022 Investments

3 investments dated 2022 · listed companies and verified rows first · show all

Aktis Oncologyaktisoncology.cominNASDAQ: AKTSAug 2022

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.

BiotechHealthtechMedical DevicesBoston, US

Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in

Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more

Avenge Bioavengebio.comJan 2022 · $45M

Biotechnology company developing the LOCOcyte cell-therapy platform for local dosing of immunotherapeutics.

Co-investorsLongitude CapitalPerceptive Xontogeny VentureRock Springs Capital

Us2us2.aiin𝕏Apr 2022

Us2.ai provides FDA-cleared AI software that automatically analyzes echocardiograms and generates structured clinical reports in real time.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investorsEast Post Road VenturesFJ LabsPartech VenturesPeak XV PartnersSequoia Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.